Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Non Operating Income (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Non Operating Income for 4 consecutive years, with -$701000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income fell 314.79% year-over-year to -$701000.0, compared with a TTM value of -$1.2 million through Sep 2025, up 3.93%, and an annual FY2024 reading of -$2.0 million, down 703.66% over the prior year.
  • Non Operating Income was -$701000.0 for Q3 2025 at Atara Biotherapeutics, down from $803000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $50.8 million in Q2 2022 and bottomed at -$818000.0 in Q2 2024.
  • Average Non Operating Income over 4 years is $3.3 million, with a median of -$169000.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 198.17% in 2025, while the deepest fall reached 1264.71% in 2025.
  • Year by year, Non Operating Income stood at $1.8 million in 2022, then crashed by 118.09% to -$329000.0 in 2023, then plummeted by 54.71% to -$509000.0 in 2024, then crashed by 37.72% to -$701000.0 in 2025.
  • Business Quant data shows Non Operating Income for ATRA at -$701000.0 in Q3 2025, $803000.0 in Q2 2025, and -$792000.0 in Q1 2025.